Vitaspring Biomedical Co Stock Analysis
| VSBC Stock | USD 1.00 0.00 0.00% |
VitaSpring Biomedical holds a debt-to-equity ratio of 0.21. With a high degree of financial leverage come high-interest payments, which usually reduce VitaSpring Biomedical's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
VitaSpring Biomedical's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. VitaSpring Biomedical's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps VitaSpring Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect VitaSpring Biomedical's stakeholders.
For many companies, including VitaSpring Biomedical, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for VitaSpring Biomedical Co, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, VitaSpring Biomedical's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that VitaSpring Biomedical's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which VitaSpring Biomedical is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of VitaSpring Biomedical to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, VitaSpring Biomedical is said to be less leveraged. If creditors hold a majority of VitaSpring Biomedical's assets, the Company is said to be highly leveraged.
VitaSpring Biomedical Co is fairly valued with Real Value of 1.0 and Hype Value of 1.0. The main objective of VitaSpring Biomedical pink sheet analysis is to determine its intrinsic value, which is an estimate of what VitaSpring Biomedical Co is worth, separate from its market price. There are two main types of VitaSpring Biomedical's stock analysis: fundamental analysis and technical analysis.
The VitaSpring Biomedical pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and VitaSpring Biomedical's ongoing operational relationships across important fundamental and technical indicators.
VitaSpring |
VitaSpring Pink Sheet Analysis Notes
About 59.0% of the company outstanding shares are owned by insiders. The company had not issued any dividends in recent years. VitaSpring Biomedical had 5:1 split on the 29th of June 2020. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. Vitaspring Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.The quote for VitaSpring Biomedical Co is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call ChengHsiang Kao at 949 202 9235 or visit https://www.vitaspringbio.com.VitaSpring Biomedical Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. VitaSpring Biomedical's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding VitaSpring Biomedical Co or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| VitaSpring Biomedical generated a negative expected return over the last 90 days | |
| VitaSpring Biomedical has some characteristics of a very speculative penny stock | |
| About 59.0% of the company outstanding shares are owned by insiders |
VitaSpring Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate VitaSpring Biomedical's market, we take the total number of its shares issued and multiply it by VitaSpring Biomedical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.VitaSpring Profitablity
The company has Profit Margin (PM) of 0.19 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.24 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.24.Technical Drivers
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of VitaSpring Biomedical, as well as the relationship between them.VitaSpring Biomedical Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in VitaSpring Biomedical price series with the more recent values given greater weights.
VitaSpring Biomedical Outstanding Bonds
VitaSpring Biomedical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. VitaSpring Biomedical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VitaSpring bonds can be classified according to their maturity, which is the date when VitaSpring Biomedical Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VMWARE INC 39 Corp BondUS928563AC98 | View | |
| VMW 22 15 AUG 31 Corp BondUS928563AL97 | View | |
| VODAFONE GROUP PLC Corp BondUS92857WAB63 | View | |
| VMW 14 15 AUG 26 Corp BondUS928563AJ42 | View | |
| VMW 18 15 AUG 28 Corp BondUS928563AK15 | View | |
| VMWARE INC Corp BondUS928563AF20 | View | |
| VODAFONE GROUP PLC Corp BondUS92857WAQ33 | View | |
| VODAFONE GROUP PLC Corp BondUS92857WBM10 | View |
VitaSpring Biomedical Debt to Cash Allocation
VitaSpring Biomedical Co currently holds 375.5 K in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. VitaSpring Biomedical has a current ratio of 4.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist VitaSpring Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, VitaSpring Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VitaSpring Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VitaSpring to invest in growth at high rates of return. When we think about VitaSpring Biomedical's use of debt, we should always consider it together with cash and equity.VitaSpring Biomedical Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the VitaSpring Biomedical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of VitaSpring Biomedical, which in turn will lower the firm's financial flexibility.VitaSpring Biomedical Corporate Bonds Issued
Most VitaSpring bonds can be classified according to their maturity, which is the date when VitaSpring Biomedical Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About VitaSpring Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how VitaSpring Biomedical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling VitaSpring shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as VitaSpring Biomedical. By using and applying VitaSpring Pink Sheet analysis, traders can create a robust methodology for identifying VitaSpring entry and exit points for their positions.
The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. Vitaspring Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding VitaSpring Biomedical to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Complementary Tools for VitaSpring Pink Sheet analysis
When running VitaSpring Biomedical's price analysis, check to measure VitaSpring Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VitaSpring Biomedical is operating at the current time. Most of VitaSpring Biomedical's value examination focuses on studying past and present price action to predict the probability of VitaSpring Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VitaSpring Biomedical's price. Additionally, you may evaluate how the addition of VitaSpring Biomedical to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |